<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Clumeck,N.</style></author><author><style face="normal" font="default" size="100%">Van Laethem,Y.</style></author><author><style face="normal" font="default" size="100%">R. Vanhoof</style></author><author><style face="normal" font="default" size="100%">Jaspar,N.</style></author><author><style face="normal" font="default" size="100%">George,G.</style></author><author><style face="normal" font="default" size="100%">Rapin,M.</style></author><author><style face="normal" font="default" size="100%">Butzler,J.P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">[Cefotaxime in the treatment of severe infections due to multiresistant Gram-negative bacilli (author's transl)]36599</style></title><secondary-title><style face="normal" font="default" size="100%">Nouv.Presse Med.</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">0</style></keyword><keyword><style  face="normal" font="default" size="100%">a</style></keyword><keyword><style  face="normal" font="default" size="100%">abstract</style></keyword><keyword><style  face="normal" font="default" size="100%">Acinetobacter Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">adverse effects</style></keyword><keyword><style  face="normal" font="default" size="100%">Ampicillin</style></keyword><keyword><style  face="normal" font="default" size="100%">article</style></keyword><keyword><style  face="normal" font="default" size="100%">bacteria</style></keyword><keyword><style  face="normal" font="default" size="100%">Cefazolin</style></keyword><keyword><style  face="normal" font="default" size="100%">Cefotaxime</style></keyword><keyword><style  face="normal" font="default" size="100%">cephalosporin</style></keyword><keyword><style  face="normal" font="default" size="100%">Cephalosporins</style></keyword><keyword><style  face="normal" font="default" size="100%">Cephalothin</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Resistance,Microbial</style></keyword><keyword><style  face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Enterobacteriaceae Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">Failure</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">im</style></keyword><keyword><style  face="normal" font="default" size="100%">Improvement</style></keyword><keyword><style  face="normal" font="default" size="100%">INFECTION</style></keyword><keyword><style  face="normal" font="default" size="100%">infections</style></keyword><keyword><style  face="normal" font="default" size="100%">IS</style></keyword><keyword><style  face="normal" font="default" size="100%">journal</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Mild</style></keyword><keyword><style  face="normal" font="default" size="100%">pathogen</style></keyword><keyword><style  face="normal" font="default" size="100%">Patient</style></keyword><keyword><style  face="normal" font="default" size="100%">patients</style></keyword><keyword><style  face="normal" font="default" size="100%">Pneumonia</style></keyword><keyword><style  face="normal" font="default" size="100%">Print</style></keyword><keyword><style  face="normal" font="default" size="100%">Pulmonary</style></keyword><keyword><style  face="normal" font="default" size="100%">RENAL</style></keyword><keyword><style  face="normal" font="default" size="100%">Renal Insufficiency</style></keyword><keyword><style  face="normal" font="default" size="100%">SB - IM</style></keyword><keyword><style  face="normal" font="default" size="100%">therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">Therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Tobramycin</style></keyword><keyword><style  face="normal" font="default" size="100%">Treat</style></keyword><keyword><style  face="normal" font="default" size="100%">treatment</style></keyword><keyword><style  face="normal" font="default" size="100%">Urinary</style></keyword><keyword><style  face="normal" font="default" size="100%">urinary tract</style></keyword><keyword><style  face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style  face="normal" font="default" size="100%">Urinary Tract Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">use</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">1981</style></year><pub-dates><date><style  face="normal" font="default" size="100%">26/2/1981</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">624</style></number><volume><style face="normal" font="default" size="100%">10</style></volume><pages><style face="normal" font="default" size="100%">622 - 624</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Cefotaxime was used to treat 33 patients with serious Gram-negative bacillary infections. The dosage varied between 1.5 g and 4 g/day in patients without renal failure. Eighteen patients had urinary tract infections, 6 had pulmonary infections and 10 had miscellaneous infections. Sixteen patients were also bacteremic. Twenty-five infections were due to pathogens resistant to ampicillin, cephalothin, gentamicin and/or tobramycin, in vitro. Fifteen infections had failed to resolve during ampicillin, cefazolin, gentamicin or tobramycin therapy. Thirty-two patients responded favourably (cure or improvement). Four patients developed superinfection with cefotaxime-resistant bacteria. One patient developed mild reversible renal insufficiency. Cefotaxime is a very active cephalosporin with potential use in serious multi-resistant enterobacteria infections</style></abstract><issue><style face="normal" font="default" size="100%">8</style></issue><custom1><style face="normal" font="default" size="100%">38125</style></custom1><section><style face="normal" font="default" size="100%">622</style></section></record></records></xml>